デフォルト表紙
市場調査レポート
商品コード
1492402

肛門がん市場:製品、がんタイプ、エンドユーザー別-2024-2030年の世界予測

Anal Cancer Market by Offering (Drugs, Therapy), Cancer Type (Adenocarcinoma, Melanoma, Squamous Cell Carcinoma), End-User - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
肛門がん市場:製品、がんタイプ、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肛門がん市場規模は2023年に10億米ドルと推計され、2024年には10億6,000万米ドルに達し、CAGR 6.38%で2030年には15億4,000万米ドルに達すると予測されます。

肛門がんは、便が体外に排出される消化管の最終セグメントである肛門管の組織に発生するがんの一種です。他のがん種と比較して比較的まれな疾患で、肛門周辺に悪性細胞が形成されます。肛門がんの最も重要な危険因子の一つはヒトパピローマウイルス(HPV)の感染であり、特に他の種類のがんとも関連している特定の株は、世界中でHPV感染の発生率が増加していることから、肛門がんの診断と治療介入の必要性が生じています。肛門がんとその症状に関する認識を高めるための世界の取り組みや政府の努力も、肛門がんソリューションの進歩に有利な環境を作り出しています。しかし、肛門がんの正確な診断は、症状が痔や軽度の裂肛のような重篤でない症状と似ていることが多いため困難であり、肛門がんの標準的なスクリーニングプロトコールがないため、早期発見率に影響します。現在の治療法は、患者のQOLや健康全般に影響を及ぼす重篤な副作用を伴うことがあります。従来の肛門がん治療に伴う副作用を軽減しながら、より効果的に肛門がんと闘う新たな方法を提供できる可能性があります。肛門がんの徴候、危険因子、予防に関する一般市民の教育と認識を高めることは、がんの早期発見とより良い治療成績につながる可能性があります。

主な市場の統計
基準年[2023] 10億米ドル
推定年[2024] 10億6,000万米ドル
予測年 [2030] 15億4,000万米ドル
CAGR(%) 6.38%

地域別の洞察

南北アメリカ地域、特に米国とカナダでは、肛門がんを含むがん治療法の研究開発に大きな注目が集まっています。肛門がんの主要な危険因子であるHPVの高い有病率が、効果的なスクリーニングと治療オプションの必要性を後押ししています。南北アメリカ地域の消費者は高度なヘルスケアサービスを利用できることが多く、より革新的で包括的な治療オプションへの購買行動に影響を与えています。市場はまた、医療保険政策やがん研究に対する政府の支援によっても形成されます。EU諸国は、がん検診プログラムと治療法の強化に注力しています。EUでは、ヘルスケアインフラとがん研究への投資が増加する傾向にあります。これは早期診断と先進治療の選択肢を促進し、質の高い治療に対する消費者の期待を形成しています。APACのヘルスケア部門は急速に進化しており、医療改革に対する政府の投資も大きいです。肛門がんの有病率の上昇と意識の高まりは、より強固な健康診断プログラムにつながっています。APACの消費者行動は政府の政策に強く影響され、伝統的な治療法と近代的な治療法の両方が採用されるようになっています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、肛門がん市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。

市場シェア分析

市場シェア分析は、肛門がん市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、肛門がん市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で肛門がんの普及が拡大
      • 肛門がん治療に対する政府の支援的投資と取り組み
    • 抑制要因
      • 治療に使用される薬剤と治療法の高価さ肛門がん
    • 機会
      • 肛門がん治療のための新薬および治療法の承認
      • 新薬の研究開発への投資
    • 課題
      • 肛門がん薬と治療法の長期的な影響
  • 市場セグメンテーション分析
    • 提供内容:肛門がんの治療オプションを改善するための継続的な進歩と規制サポート
    • がんの種類:扁平上皮がんの症例が増加しており、迅速かつ効果的な診断と治療介入の必要性が高まっています。
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 肛門がん市場:提供別

  • 薬物
  • 治療

第7章 肛門がん市場がんの種類別

  • 腺がん
  • 悪性黒色腫
  • 扁平上皮がん

第8章 肛門がん市場:エンドユーザー別

  • 外来手術センター
  • 病院
  • 専門クリニック

第9章 南北アメリカの肛門がん市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の肛門がん市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの肛門がん市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • FDA、進行性尿路上皮がんに対するニボルマブ併用療法を認可
    • FDA、化学療法不足に対処するため中国製シスプラチンの一時輸入を承認
    • アレンビックファーマ、フルオロウラシル注射剤の米国FDA承認を取得
  • 戦略分析と提言

第13章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. ANAL CANCER MARKET RESEARCH PROCESS
  • FIGURE 2. ANAL CANCER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANAL CANCER MARKET DYNAMICS
  • FIGURE 7. GLOBAL ANAL CANCER MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ANAL CANCER MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANAL CANCER MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ANAL CANCER MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANAL CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANAL CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. ANAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANAL CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANAL CANCER MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ANAL CANCER MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANAL CANCER MARKET SIZE, BY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ANAL CANCER MARKET SIZE, BY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANAL CANCER MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ANAL CANCER MARKET SIZE, BY CARBOPLATIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANAL CANCER MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ANAL CANCER MARKET SIZE, BY CISPLATIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANAL CANCER MARKET SIZE, BY FLUOROURACIL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ANAL CANCER MARKET SIZE, BY FLUOROURACIL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANAL CANCER MARKET SIZE, BY LEUCOVORIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ANAL CANCER MARKET SIZE, BY LEUCOVORIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANAL CANCER MARKET SIZE, BY MITOMYCIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ANAL CANCER MARKET SIZE, BY MITOMYCIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANAL CANCER MARKET SIZE, BY OXALIPLATIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ANAL CANCER MARKET SIZE, BY OXALIPLATIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ANAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANAL CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ANAL CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ANAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ANAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANAL CANCER MARKET SIZE, BY MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL ANAL CANCER MARKET SIZE, BY MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL ANAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL ANAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL ANAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS ANAL CANCER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ANAL CANCER MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES ANAL CANCER MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 320. ITALY ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 321. ITALY ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 322. ITALY ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 323. ITALY ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 324. ITALY ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 330. NETHERLANDS ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 332. NETHERLANDS ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 334. NETHERLANDS ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 336. NETHERLANDS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 337. NETHERLANDS ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 338. NETHERLANDS ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 339. NIGERIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 340. NIGERIA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 341. NIGERIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 342. NIGERIA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 343. NIGERIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 344. NIGERIA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 345. NIGERIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 346. NIGERIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 347. NIGERIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 348. NIGERIA ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 349. NORWAY ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 350. NORWAY ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 351. NORWAY ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 352. NORWAY ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 353. NORWAY ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 354. NORWAY ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 355. NORWAY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 356. NORWAY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 357. NORWAY ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 358. NORWAY ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 359. POLAND ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 360. POLAND ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 361. POLAND ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 362. POLAND ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 363. POLAND ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 364. POLAND ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 365. POLAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 366. POLAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 367. POLAND ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 368. POLAND ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 369. QATAR ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 370. QATAR ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 371. QATAR ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 372. QATAR ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 373. QATAR ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 374. QATAR ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 375. QATAR ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 376. QATAR ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 377. QATAR ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 378. QATAR ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 379. RUSSIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 380. RUSSIA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 381. RUSSIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 382. RUSSIA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 383. RUSSIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 384. RUSSIA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 385. RUSSIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 386. RUSSIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 387. RUSSIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 388. RUSSIA ANAL CANCER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 389. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 390. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 391. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 392. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 393. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 394. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 395. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 396. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 397. SAUDI ARABIA AN
目次
Product Code: MRR-CD5A9334D00D

[186 Pages Report] The Anal Cancer Market size was estimated at USD 1.00 billion in 2023 and expected to reach USD 1.06 billion in 2024, at a CAGR 6.38% to reach USD 1.54 billion by 2030.

Anal cancer is a type of cancer that develops in the tissues of the anal canal, the final segment of the gastrointestinal tract through which stool exits the body. It is a relatively rare disease compared to other types of cancer and involves the formation of malignant cells in the area around the anus. One of the most significant risk factors for anal cancer is infection with Human Papillomavirus (HPV), particularly certain strains that are also linked to other types of cancers, and the growing incidences of HPV infections across the world create a need for anal cancer diagnostics and therapeutic interventions. Global initiatives and efforts by the government to raise awareness about anal cancer and its symptoms also create a favorable environment for the progress of anal cancer solutions. However, precise diagnosis of anal cancer can be challenging as symptoms often resemble less severe conditions such as hemorrhoids or minor anal fissures, and the lack of standard screening protocol for anal cancer affects early detection rates. Current treatments can have severe side effects affecting the quality of life and overall health of the patient. Exploring immunotherapy treatments could offer new ways to combat anal cancer more effectively while reducing the side effects associated with traditional anal cancer treatments. Enhancing public education and awareness about the signs, risk factors, and prevention of anal cancer could lead to earlier cancer detection and better treatment outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 1.00 billion
Estimated Year [2024] USD 1.06 billion
Forecast Year [2030] USD 1.54 billion
CAGR (%) 6.38%

Regional Insights

In the Americas region, particularly the U.S. and Canada, there is a significant focus on the research and development of cancer treatments, including those for anal cancer. The high prevalence of HPV, a major risk factor for anal cancer, drives a need for effective screening and treatment options. Consumers in the Americas region often have access to advanced healthcare services, influencing purchasing behaviors towards more innovative and comprehensive treatment options. The market is also shaped by health insurance policies and government support for cancer research. Countries within the EU are focused on enhancing cancer screening programs and treatment methodologies. EU showcases a trend towards increasing investment in healthcare infrastructure and cancer research. This promotes early diagnosis and advanced treatment options, shaping consumer expectations towards high-quality care. APAC's healthcare sector is rapidly evolving, with significant government investment in healthcare reform. The rising prevalence of anal cancer and increasing awareness have led to more robust health screening programs. Consumer behavior in APAC is strongly influenced by government policies, leading to increased adoption of both traditional and modern treatment options.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Anal Cancer Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Growing prevalence of anal cancer across the globe
      • Supportive government investments and initiatives for anal cancer treatments
    • Market Restraints
      • Expensive nature of drugs and therapies used to treat anal cancer
    • Market Opportunities
      • Approvals for new drugs and therapies for anal cancer treatment
      • Investments in research and development of novel drugs
    • Market Challenges
      • Long-term consequences of anal cancer drugs and therapies
  • Market Segmentation Analysis
    • Offering: Ongoing advancements and regulatory support to improve the therapy options for anal cancer
    • Cancer Type: Rising cases of squamous cell carcinomas and need for quick and effective diagnostics and treatment interventions
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Anal Cancer Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Anal Cancer Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Sanctions Nivolumab Combo for Advanced Urothelial Carcinoma

The FDA has approved a novel treatment regimen for unresectable or metastatic urothelial carcinoma, combining nivolumab with cisplatin and gemcitabine. This approval was based on compelling evidence from a clinical study where the primary endpoints were overall survival and progression-free survival. These outcomes were rigorously evaluated by a blinded independent central review, adhering to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. [Published On: 2024-03-25]

FDA Approves Temporary Import of Chinese-Made Cisplatin to Address Chemotherapy Shortage

In response to the critical shortage of chemotherapy treatments in the United States, the Food and Drug Administration (FDA) has authorized the temporary importation of cisplatin, a cancer-fighting drug manufactured by Qilu Pharmaceutical in China. This approval permits the distribution of the drug, packaged in 50-milligram vials, by Canadian pharmaceutical company Apotex. This temporary measure is aimed at mitigating the ongoing scarcity of essential chemotherapy medications across the country. [Published On: 2023-04-01]

Alembic Pharma Secures USFDA Approval for Fluorouracil Injection

Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (USFDA) for its Fluorouracil injection USP, Pharmacy Bulk Vial. This generic medication is confirmed to be therapeutically equivalent to Spectrum Pharmaceuticals' Fluorouracil Injection. The approved drug is designated for treating various types of adenocarcinomas, including colon, rectum, breast, stomach, and pancreatic cancers. This approval marks a crucial advancement in the availability of essential cancer treatments. [Published On: 2023-03-06]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Anal Cancer Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Anal Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., ADVANCED MARKER DISCOVERY, S.L., Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, bioMerieux SA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Ipsen Pharma, Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Qilu Pharmaceutical Co. Ltd, Regeneron Pharmaceuticals Inc., SANOFI WINTHROP INDUSTRIE, Taj Pharmaceuticals Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Anal Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Offering
    • Drugs
      • Carboplatin
      • Cisplatin
      • Fluorouracil
      • Leucovorin
      • Mitomycin
      • Oxaliplatin
    • Therapy
      • Chemotherapy
      • Radiation Therapy
      • Targeted Therapy
  • Cancer Type
    • Adenocarcinoma
    • Melanoma
    • Squamous Cell Carcinoma
  • End-User
    • Ambulatory Surgical Centers
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of anal cancer across the globe
      • 5.1.1.2. Supportive government investments and initiatives for anal cancer treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive nature of drugs and therapies used to treat anal cancer
    • 5.1.3. Opportunities
      • 5.1.3.1. Approvals for new drugs and therapies for anal cancer treatment
      • 5.1.3.2. Investments in research and development of novel drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Long-term consequences of anal cancer drugs and therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Ongoing advancements and regulatory support to improve the therapy options for anal cancer
    • 5.2.2. Cancer Type: Rising cases of squamous cell carcinomas and need for quick and effective diagnostics and treatment interventions
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Anal Cancer Market, by Offering

  • 6.1. Introduction
  • 6.2. Drugs
  • 6.3. Therapy

7. Anal Cancer Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Adenocarcinoma
  • 7.3. Melanoma
  • 7.4. Squamous Cell Carcinoma

8. Anal Cancer Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Anal Cancer Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anal Cancer Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anal Cancer Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Sanctions Nivolumab Combo for Advanced Urothelial Carcinoma
    • 12.3.2. FDA Approves Temporary Import of Chinese-Made Cisplatin to Address Chemotherapy Shortage
    • 12.3.3. Alembic Pharma Secures USFDA Approval for Fluorouracil Injection
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio